OR WAIT null SECS
October 04, 2021
Takeda will use Selecta Bioscience’s ImmTOR platform to develop gene therapies for lysosomal storage disorders.
October 03, 2021
Reformulation strategies are useful tools for more than just stretching out the potential return on investment for a product.
October 01, 2021
DRI’s subsidiary has acquired a royalty interest in Oracea (doxycycline) for $46.4 million.
AstraZeneca’s acquisition of Caelum Biosciences gives them access to CAEL-101, a promising light chain amyloidosis treatment.
Pure Psyence, Pure Extracts and Psyence’s joint venture company, will develop psilocybin-derived treatments.
Merck’s 11.5 billion acquisition of Acceleron gives them access to their lead therapeutic candidate, sotatercept.
September 29, 2021
KSL Biomedical announced their expansion into Canada with the acquisition of Pulse Scientific and the incorporation of KSL Biomedical Canada.
September 23, 2021
Boehringer Ingelheim to develop novel cancer therapies by leveraging Abexxa’s breakthrough antibody-based drugs.
September 22, 2021
Novartis’ acquisition of Arctos Medical could lead to significant advancements in optogenetic therapies for patients with vision loss.
September 17, 2021
Democrats failed to gain sufficient support to advance long-debated legislation to permit Medicare drug price negotiations.